LC-MS/MS method for determination of megestrol in human plasma and its application in bioequivalence study

Abstract

A rapid and highly selective liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of megestrol in human plasma was described using medrysone as internal standard (IS). Blood samples were collected from 20 healthy volunteers after oral administration of 160 mg megestrol acetate dispersible tablets. The analytes were extracted by liquid-liquid extraction procedure and separated on a hanbon lichrospher column with the mobile phase of methanol and water containing 0.1% formic acid and 20 mmol/L ammonium acetate (5:1, v/v). Positive ion electrospray ionization with multiple reaction-monitoring mode (MRM) was employed by monitoring the transitions m/z 385.5–325.4 and m/z 387.5–327.4 for megestrol and medrysone, respectively. Under the isocratic separation conditions, the chromatographic run time was approximately 2.54 min for megestrol and 2.59 min for medrysone. The calibration curve range was from 0.5 to 200.0 ng/mL. The inter-batch and intra-batch precision and accuracy were less than 5.2% relative standard deviation (RSD) and 6.4% relative error (RE). The proposed method was successfully applied in the bioequivalence study of megestrol acetate dispersible tablets.

Keywords

megestrol / bioequivalence / liquid chromatography-tandem mass spectrometry

References

[1] LogmansA, MousHVH, BontenbalM, et al.. Results of curettage for postmenopausal vaginal bleeding in women treated with tamoxifen and megestrol acetate for progressive metastatic breast carcinoma. Eur J Obstet Gyn R B, 1994, 56(3): 173-176

[2] JonatW, HowellA, BlomqvistC, et al.. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Euro J Cancer, 1996, 32(3): 404-412

[3] StuartNS, WarwickJ, BlackledgeGR, et al.. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Euro J Cancer, 1996, 32(11): 1888-1892

[4] LicchettaA, CorrealeP, MigaliC, et al.. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J Chemother, 2010, 22(3): 201-204

[5] MateenF, JatoiA. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr, 2006, 25(5): 711-715

[6] WestmanG, BergmanB, AlbertssonM, et al.. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. Euro J Cancer, 1999, 35(4): 586-595

[7] De ConnoF, MartiniC, ZeccaE, et al.. Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Euro J Cancer, 1998, 34(11): 1705-1709

[8] Pascual LópezA, Roqué i FigulsM, Urrútia CuchiG, et al.. Systematic review of megestrol acetate in the treatment of anorexia-cachxia syndrome. J Pain Sym Man, 2004, 27(4): 360-369

[9] FietkauR, RieplM, KettnerH, et al.. Supportive use of magestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Euro J Cancer, 1997, 33(1): 75-79

[10] ChenHC, LeungSW, WangCJ, et al.. Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiother Oncol, 1997, 43(1): 75-79

[11] HongS, JeongIG, YouD, et al.. Safty of megestrol acetate in palliating anorexia-cachexia syndrome in patients with castration resistant prostate cancer. J Hematol Oncol, 2013, 28(5): 687-692

[12] AdlercreutzH, EriksenPB, ChristensenMS. Plasma concentrations of megestrol acetate and medroxyprogesterone acetate after single oral administration to healthy subjects. J Pharmac Biomed Anal, 1983, 1(2): 153-162

[13] GaverRC, MovahhedHS, FarmenRH, et al.. Liquid chromatographic procedure for the quantitative analysis of megestrol acetate in human plasma. J Pharm Sci, 1985, 74(6): 664-667

[14] JosephG, TimponeDJW, NingL, et al.. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrom. AIDS Res Human Retroviruses, 1997, 13(4): 305-315

[15] Guedes-AlonsoR, Sosa-FerreraZ, Santana-RodríguezJJ. Simultaneous determination of hormonal residues in treated waters using ultrahigh performance liquid chromatography-tandem mass spectrometry. J Anal Methods Chem, 2013, 2013: 210653